Cargando…

Renal and Glucose-Lowering Effects of Empagliflozin and Dapagliflozin in Different Chronic Kidney Disease Stages

Objective: The objective of this study was to investigate the effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on renal function in different stages of chronic kidney disease (CKD). Design and Methods: We conducted a retrospective cohort study using longitudinal claims data from May 2016...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Yi-Hsuan, Huang, Yu-Yao, Hsieh, Sheng-Hwu, Sun, Jui-Hung, Chen, Szu-Tah, Lin, Chia-Hung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883723/ https://www.ncbi.nlm.nih.gov/pubmed/31824432 http://dx.doi.org/10.3389/fendo.2019.00820

Ejemplares similares

Impact of Carbohydrate on Glucose Variability in Patients with Type 1 Diabetes Assessed Through Professional Continuous Glucose Monitoring: A Retrospective Study
por: Lin, Yi-Hsuan, et al.
Publicado: (2019)

Study comparing the efficacy and renal safety for patients with diabetes switching from dapagliflozin to empagliflozin
por: Yang, Ai-Yu, et al.
Publicado: (2020)

Ankle-Brachial Index Is Independently Associated With Cardiovascular Outcomes and Foot Ulcers in Asian Patients With Type 2 Diabetes Mellitus
por: Yang, Ming-Chi, et al.
Publicado: (2021)

Corrigendum: Ankle-Brachial Index Is Independently Associated With Cardiovascular Outcomes and Foot Ulcers in Asian Patients With Type 2 Diabetes Mellitus
por: Yang, Ming-Chi, et al.
Publicado: (2022)

Dapagliflozin versus empagliflozin in patients with chronic kidney disease
por: Alnsasra, Hilmi, et al.
Publicado: (2023)

Regimen comprising GLP-1 receptor agonist and basal insulin can decrease the effect of food on glycemic variability compared to a pre-mixed insulin regimen
por: Lin, Yi-Hsuan, et al.
Publicado: (2022)

Evaluation of Disease Complications Among Adults With Type 1 Diabetes and a Family History of Type 2 Diabetes in Taiwan
por: Lin, Chia-Hung, et al.
Publicado: (2021)

Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study
por: Lin, Yi-Hsuan, et al.
Publicado: (2018)

Successful Applications of Food-Assisted and -Simulated Training Model of Thyroid Radiofrequency Ablation
por: Li, Yan-Rong, et al.
Publicado: (2022)

Gender-Specific Variation in the Prognosis of Papillary Thyroid Cancer TNM Stages II to IV
por: Hsieh, Sheng-Hwu, et al.
Publicado: (2012)

Glucose Variability and β- Cell Response by GLP-1 Analogue added-on CSII for Patients with Poorly Controlled Type 2 Diabetes
por: Lin, Chia-Hung, et al.
Publicado: (2015)

Exposure–Response Analysis of the Sodium–Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes
por: van der Hoek, Sjoukje, et al.
Publicado: (2023)

The Lower Limit of Reference of Urinary Albumin/Creatinine Ratio and the Risk of Chronic Kidney Disease Progression in Patients With Type 2 Diabetes Mellitus
por: Tang, Wei-Hua, et al.
Publicado: (2022)

Quantitative effects of sodium–glucose cotransporter-2 inhibitors dapagliflozin and empagliflozin on quality of life in heart failure patients
por: Wang, Dong-Dong, et al.
Publicado: (2022)

Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study
por: Shao, Shih-Chieh, et al.
Publicado: (2019)

Eligibility of Dapagliflozin and Empagliflozin in a Real-World Heart Failure Population
por: Håkansson, Erik, et al.
Publicado: (2021)

Comparative Assessment of the Long-Term Effectiveness and Safety of Dapagliflozin and Empagliflozin as Add-on Therapy to Hypoglycemic Drugs in Patients with Type 2 Diabetes
por: Yang, Ai-Yu, et al.
Publicado: (2022)

Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease
por: Lim, Jayoung, et al.
Publicado: (2022)

Use and effectiveness of dapagliflozin in patients with type 2 diabetes mellitus: a multicenter retrospective study in Taiwan
por: Chen, Jung-Fu, et al.
Publicado: (2020)

Dapagliflozin and Empagliflozin in Heart Failure with Reduced Ejection Fraction: A Retrospective Study
por: Hao, Zhengyang, et al.
Publicado: (2022)

Diagnostic value of adrenal iodine-131 6-beta-iodomethyl-19-norcholesterol scintigraphy for primary aldosteronism: a retrospective study at a medical center in North Taiwan
por: Wu, Ming-Hsien, et al.
Publicado: (2019)

Empagliflozin reduces diffuse myocardial fibrosis by extracellular volume mapping: A meta-analysis of clinical studies
por: Wang, Haipeng, et al.
Publicado: (2022)

Empagliflozin Attenuates Obesity-Related Kidney Dysfunction and NLRP3 Inflammasome Activity Through the HO-1–Adiponectin Axis
por: Ye, Tongtong, et al.
Publicado: (2022)

Case Report: High-Calorie Glucose Infusion and Tight Glycemic Control in Ameliorating Refractory Acidosis of Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis
por: Wan Azman, Siti Sanaa, et al.
Publicado: (2022)

Sodium glucose co-transporter 2 (SGLT2) inhibition via dapagliflozin improves diabetic kidney disease (DKD) over time associatied with increasing effect on the gut microbiota in db/db mice
por: Wu, Jiajia, et al.
Publicado: (2023)

No Cytotoxic and Inflammatory Effects of Empagliflozin and Dapagliflozin on Primary Renal Proximal Tubular Epithelial Cells under Diabetic Conditions In Vitro
por: Baer, Patrick C., et al.
Publicado: (2020)

Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling
por: Sokolov, Victor, et al.
Publicado: (2020)

Dapagliflozin Attenuates Renal Tubulointerstitial Fibrosis Associated With Type 1 Diabetes by Regulating STAT1/TGFβ1 Signaling
por: Huang, Fengjuan, et al.
Publicado: (2019)

Association between triglyceride-glucose index and risk of end-stage renal disease in patients with type 2 diabetes mellitus and chronic kidney disease
por: Gao, Yue-Ming, et al.
Publicado: (2023)

Dapagliflozin Ameliorates Lipopolysaccharide Related Acute Kidney Injury in Mice with Streptozotocin-induced Diabetes Mellitus
por: Chi, Po-Jui, et al.
Publicado: (2022)

Evaluation of recurrence risk in patients with papillary thyroid cancer through tumor-node-metastasis staging: A single-center observational study in Taiwan
por: Sun, Jui-Hung, et al.
Publicado: (2022)

Comparison of safety and efficacy of dapagliflozin and empagliflozin in type 2 diabetes mellitus patients in India
por: Varshney, Amit, et al.
Publicado: (2023)

Professional Continuous Glucose Monitoring for the Identification of Type 1 Diabetes Mellitus Among Subjects With Insulin Therapy
por: Chen, Yin-Chun, et al.
Publicado: (2015)

Dapagliflozin Attenuates Hyperglycemia Related Osteoporosis in ZDF Rats by Alleviating Hypercalciuria
por: Wang, Ji-Yu, et al.
Publicado: (2019)

A Network Meta-Analysis of the Dose–Response Effects of Dapagliflozin on Efficacy and Safety in Adults With Type 1 Diabetes
por: Li, Yinhui, et al.
Publicado: (2022)

Sodium glucose co-transporter 2 inhibition with empagliflozin on metabolic, cardiac and renal outcomes in recent cardiac transplant recipients (EMPA-HTx): protocol for a randomised controlled trial
por: Raven, Lisa Mary, et al.
Publicado: (2023)

Corrigendum: Dapagliflozin Attenuates Hyperglycemia Related Osteoporosis in ZDF Rats by Alleviating Hypercalciuria
por: Wang, Ji-Yu, et al.
Publicado: (2020)

Dapagliflozin Modulates the Fecal Microbiota in a Type 2 Diabetic Rat Model
por: Yang, Mei, et al.
Publicado: (2020)

Pharmacokinetic and pharmacodynamic drug–drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers
por: Kim, Dasohm, et al.
Publicado: (2023)

Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome
por: Akiyama, Hiroki, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a2e95tbr3p3qgvs3td9jnjovuk